Author:
Zeyen Christoph,Kinberger Maria,Kriedemann Helene,Pfäfflin Frieder,Tober-Lau Pinkus,Huang Leu,Corman Victor Max,Nast Alexander,Sander Leif Erik,Kurth Florian,Werner Ricardo Niklas
Abstract
Abstract
Background
Cases of mpox have been reported worldwide since May 2022. Limited knowledge exists regarding the long-term course of this disease. To assess sequelae in terms of scarring and quality of life (QoL) in mpox patients 4–6 months after initial infection.
Methods
Prospective observational study on clinical characteristics and symptoms of patients with polymerase chain reaction (PCR)-confirmed mpox, including both outpatients and inpatients. Follow-up visits were conducted at 4–6 months, assessing the Patient and Observer Scar Assessment Scale (POSAS), the Dermatology Life Quality Index (DLQI) and sexual impairment, using a numeric rating scale (NRS) from 0 to 10.
Results
Forty-three patients, age range 19–64 years, 41 men (all identifying as MSM) and 2 women, were included. Upon diagnosis, skin or mucosal lesions were present in 93.0% of cases, with 73.3% reporting pain (median intensity: 8, Q1-Q3: 6–10). Anal involvement resulted in a significantly higher frequency of pain than genital lesions (RR: 3.60, 95%-CI: 1.48–8.74). Inpatient treatment due to pain, superinfection, abscess or other indications was required in 20 patients (46.5%). After 4–6 months, most patients did not have significant limitations, scars or pain. However, compared to patients without such complications, patients with superinfection or abscess during the acute phase had significantly more extensive scar formation (median PSAS: 24.0 vs. 11.0, p = 0.039) and experienced a significantly greater impairment of their QoL (median DLQI: 2.0 vs. 0.0, p = 0.036) and sexuality (median NRS: 5.0 vs. 0.0, p = 0.017).
Conclusion
We observed a wide range of clinical mpox manifestations, with some patients experiencing significant pain and requiring hospitalization. After 4–6 months, most patients recovered without significant sequelae, but those with abscesses or superinfections during the initial infection experienced a significant reduction in QoL and sexuality. Adequate treatment, including antiseptic and antibiotic therapy during the acute phase, may help prevent such complications, and hence, improve long-term outcomes.
Funder
Charité - Universitätsmedizin Berlin
Publisher
Springer Science and Business Media LLC
Reference20 articles.
1. Jezek Z, Gromyko AI, Szczeniowski MV. Human monkeypox. J Hyg Epidemiol Microbiol Immunol. 1983;27(1):13–28.
2. World Health Organization. 2022-23 Mpox (Monkeypox) Outbreak: Global Trends 2023 [Available from: https://worldhealthorg.shinyapps.io/mpx_global/.
3. Gessain A, Nakoune E, Yazdanpanah Y, Monkeypox. N Engl J Med. 2022;387(19):1783–93.
4. World Health Organization. MPOX Fact Sheet 2023 [Available from: https://www.who.int/news-room/fact-sheets/detail/monkeypox.
5. Bunge EM, Hoet B, Chen L, Lienert F, Weidenthaler H, Baer LR, Steffen R. The changing epidemiology of human monkeypox-A potential threat? A systematic review. PLoS Negl Trop Dis. 2022;16(2):e0010141.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献